# Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

> **NCT04669496** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 178 (actual)

## Conditions studied

- Intrahepatic Cholangiocarcinoma
- PD1 Antibody
- Lenvatinib
- Gemox Chemotherapy

## Interventions

- **DRUG:** Neoadjuvant treatment

## Key facts

- **NCT ID:** NCT04669496
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-01-20
- **Primary completion:** 2025-04-30
- **Final completion:** 2026-12
- **Target enrollment:** 178 (ACTUAL)
- **Last updated:** 2025-09-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04669496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04669496, "Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04669496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*